Company intelligence / Profile preview

Chongqing Bovax Biopharmaceutical

Chongqing, Chongqing, China

Ownership: Private
Employees: ~500
Development stage: Other

Overview

Chongqing Bovax is a leading Chinese biotechnology company specializing in recombinant vaccines. Its lead candidate is a 9-valent HPV vaccine currently in Phase 3 clinical trials, positioned to be one of the first domestically produced alternatives to Gardasil 9 in the Chinese market. The company also has 4-valent and 2-valent HPV vaccines in late-stage development.

Therapeutic areas: OncologyInfectious Diseases
Modalities: VaccineRecombinant protein
Industry: Biotech

Partnerships

Chongqing Zhifei Biological Products

Beyond the preview

Go deeper on Chongqing Bovax Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chongqing Bovax Biopharmaceutical.

Explore the full profile